Trastuzumab competition in the European market is heating up, as Mundipharma announced yesterday that it has officially launched Celltrion’s biosimilar, Herzuma.
Trastuzumab competition in the European market is heating up as Mundipharma announced yesterday that it has officially launched Celltrion’s trastuzumab biosimilar, Herzuma. The product is now available in both the United Kingdom and Germany, with further launches across Europe anticipated in the coming months. Celltrion has granted Mundipharma exclusive distribution rights to the biosimilar in the United Kingdom, Germany, Italy, Belgium, Luxembourg, and the Netherlands.
The biosimilar, referencing Roche’s Herceptin, was granted marketing authorization on February 9, 2018, following a positive opinion and recommendation for approval by the European Medicine’s Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) in December 2017. Herzuma has been approved for the treatment of patients with early breast cancer, metastatic breast cancer, or metastatic gastric cancer whose tumors have either HER2 overexpression or HER2 gene amplification.
“Building on our partnership with Celltrion Healthcare, we are pleased to announce that biosimilar trastuzumab is now available in Europe with national launches commencing in both the [United Kingdom] and Germany. The availability of a biosimilar trastuzumab will provide an alternative treatment option to the thousands of eligible patients across Europe with early breast cancer, metastatic breast cancer, or metastatic gastric cancer,” said Richard Trollope, head of oncology and biosimilars at Mundipharma, in a statement.
This launch comes on the heels of the commercial availability of Ontruzant, developed by Samsung Bioepis, which became the first trastuzumab biosimilar introduced in Europe when it entered the UK market on March 8, 2018. The biosimilars will now be competing for market share with brand-name Herceptin, which is among the top-selling drugs in the global marketplace, having earned $6.75 billion in sales in 2016.
In addition to launching its drug in the United Kingdom, Samsung Bioepis also filed for US regulatory review of its trastuzumab biosimilar. However, the potential to launch a trastuzumab biosimilar in the US market has proven difficult. Pfizer received a Complete Response Letter (CRL) on April 23, 2018 from the FDA requesting more information about their trastuzumab biosimilar; adding to Celltrion receiving its own CRL on April 5, 2018 due to the FDA citing concerns about manufacturing practices.
To date, the FDA has only approved 1 trastuzumab biosimilar, Ogivri, developed by Mylan and Biocon, though no launch date has yet been set.
FDA and Industry Experts Unpack Biosimilar Device Requirements
October 23rd 2024At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for biosimilars and interchangeable biosimilars, highlighting new approaches to comparative use human factors studies, regulatory challenges, and alternative validation methods.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Eye on Pharma: Aflibercept Legal Drama; PBM, Humira Biosimilars; Denosumab Regulatory Review
October 15th 2024Regeneron appeals legal decision after judge refuses to block an aflibercept biosimilar; Prime Therapeutics, a pharmacy benefit manager (PBM), becomes the latest to offer biosimilars referencing Humira (adalimumab) at a low cost; the FDA and European Medicines Agency accept a denosumab biosimilar candidate for review.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Samsung Bioepis Report Showcases Adalimumab Biosimilar Growth in Market Share
October 11th 2024Adalimumab biosimilars have seen a significant increase in market share, from 2% in early 2024 to 22%, as payers and pharmacy benefit managers begin to prioritize these biosimilars over the reference product, Humira.
Sandoz Report: A Unified Approach to Overcoming Drug Shortages
October 10th 2024A report from Sandoz emphasizes the need for collaboration among stakeholders to eliminate drug shortages impacting over 90% of hospital systems in the US, recommending policy changes and actions to address the ongoing issue, which has caused treatment delays and increased costs.